SunTrust Banks, Inc. began coverage on shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) in a research report released on Wednesday, November 8th, MarketBeat reports. The brokerage issued a buy rating and a $26.00 price target on the biopharmaceutical company’s stock. SunTrust Banks also issued estimates for Abeona Therapeutics’ Q3 2017 earnings at ($0.23) EPS, Q4 2017 earnings at ($0.24) EPS, FY2017 earnings at ($0.81) EPS, Q1 2018 earnings at ($0.25) EPS, Q2 2018 earnings at ($0.30) EPS, Q3 2018 earnings at ($0.30) EPS, Q4 2018 earnings at ($0.28) EPS, FY2018 earnings at ($1.13) EPS, FY2019 earnings at ($1.09) EPS, FY2020 earnings at ($1.04) EPS and FY2021 earnings at ($0.80) EPS.
A number of other equities analysts also recently issued reports on the company. BidaskClub upgraded Abeona Therapeutics from a buy rating to a strong-buy rating in a research note on Wednesday, July 12th. Cantor Fitzgerald set a $21.00 target price on Abeona Therapeutics and gave the company a buy rating in a research report on Tuesday, July 18th. Maxim Group set a $17.00 target price on Abeona Therapeutics and gave the company a buy rating in a research report on Tuesday, August 29th. Zacks Investment Research upgraded Abeona Therapeutics from a hold rating to a buy rating and set a $10.00 target price on the stock in a research report on Tuesday, July 11th. Finally, HC Wainwright reissued a buy rating and set a $20.00 price target on shares of Abeona Therapeutics in a report on Thursday, August 24th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of $26.10.
Shares of Abeona Therapeutics (NASDAQ:ABEO) opened at $16.65 on Wednesday. Abeona Therapeutics has a fifty-two week low of $4.05 and a fifty-two week high of $22.75.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. State Street Corp purchased a new stake in Abeona Therapeutics during the second quarter worth $1,900,000. Point72 Asset Management L.P. purchased a new stake in Abeona Therapeutics during the third quarter worth $3,527,000. Northern Trust Corp lifted its holdings in Abeona Therapeutics by 406.3% during the second quarter. Northern Trust Corp now owns 257,668 shares of the biopharmaceutical company’s stock worth $1,649,000 after buying an additional 206,775 shares during the period. EAM Investors LLC purchased a new stake in Abeona Therapeutics during the third quarter worth $2,509,000. Finally, Vanguard Group Inc. lifted its holdings in Abeona Therapeutics by 11.2% during the second quarter. Vanguard Group Inc. now owns 1,081,670 shares of the biopharmaceutical company’s stock worth $6,922,000 after buying an additional 108,730 shares during the period. Hedge funds and other institutional investors own 41.95% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was published by BBNS and is the sole property of of BBNS. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://baseballnewssource.com/markets/abeona-therapeutics-inc-abeo-now-covered-by-suntrust-banks-inc/1768075.html.
About Abeona Therapeutics
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with our FREE daily email newsletter.